FSC
BMRN icon

Full Sail Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Full Sail Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$382K Buy
7,056
+602
+9% +$34.4K 0.02% 191
2025
Q2 		$355K Buy
+6,454
New +$380K 0.02% 156

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Full Sail Capital's BMRN Position: Q3 2025 in Review

Full Sail Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 9.3% in Q3 2025, buying an estimated $34.4K and bringing the position to 7,056 shares worth $382K. The position accounts for 0.02% of the portfolio, ranked #191.

Full Sail Capital first reported a position in BMRN in Q2 2025 and has held it in 2 quarters since. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Full Sail Capital held 7,056 shares of BioMarin Pharmaceuticals worth $382K as of Q3 2025.
  • Full Sail Capital bought 602 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $34.4K.
  • BioMarin Pharmaceuticals made up 0.02% of Full Sail Capital's portfolio in Q3 2025, its #191 holding.
  • Full Sail Capital first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Full Sail Capital's 13F filing for Q3 2025, filed 14 Nov 2025.